Erivedge

Erivedge (vismodegib) is a medication used in the treatment of basal-cell carcinoma, a type of skin cancer. It is an oral medication that inhibits the Hedgehog signaling pathway, which is implicated in the development of basal-cell carcinoma. Erivedge is particularly used for patients with advanced basal-cell carcinoma that has metastasized or cannot be treated with surgery or radiation therapy.

Mechanism of Action

Erivedge works by targeting and inhibiting the Smoothened (SMO) receptor, a key component of the Hedgehog signaling pathway. This pathway is crucial for cell growth and differentiation during embryonic development, but its abnormal activation is associated with the development of various cancers, including basal-cell carcinoma. By inhibiting the SMO receptor, Erivedge effectively blocks the Hedgehog pathway, thereby reducing the proliferation of cancer cells.

Indications

Erivedge is indicated for the treatment of:

• Metastatic basal-cell carcinoma
• Locally advanced basal-cell carcinoma that has recurred following surgery or radiation therapy, or in patients who are not candidates for surgery or radiation therapy

Administration and Dosage

Erivedge is administered orally, typically in the form of a capsule. The recommended dosage is one 150 mg capsule taken once daily, with or without food. It is important for patients to follow their healthcare provider's instructions regarding the duration of treatment.

Side Effects

Common side effects of Erivedge include:

• Muscle spasms
• Hair loss
• Fatigue
• Nausea
• Diarrhea
• Weight loss
• Loss of appetite

Serious side effects may include severe skin reactions, liver problems, and birth defects if taken during pregnancy. Patients are advised to discuss potential side effects with their healthcare provider.

Contraindications

Erivedge is contraindicated in:

• Pregnant women, due to the risk of severe birth defects
• Women who are breastfeeding
• Patients with known hypersensitivity to vismodegib or any of its components

Monitoring and Precautions

Patients taking Erivedge should be monitored regularly for side effects and response to treatment. Women of childbearing potential should use effective contraception during treatment and for a period after the last dose, as advised by their healthcare provider.

Related Pages

• Basal-cell carcinoma
• Hedgehog signaling pathway
• Skin cancer
• Oral medication
• Smoothened receptor
• Cancer treatment